Skip to content
Winnowleaf home

Condition

HIV Infection

HIV is a virus that infects the immune system's CD4 cells, gradually weakening the body's defenses against other infections. Enfuvirtide has the strongest evidence, and a phase III trial found it lowered viral load more than an optimized background regimen alone at 24 weeks in people who had already tried other HIV medicines. Those results mostly apply to people with that history and to 24 weeks, so they say less about longer-term outcomes.

Sources: PMID 35672866

Supplements studied
0
Medicines and peptides
1
Graded outcomes
5
No supplement studies yetWe haven’t found supplement studies for HIV Infection. The medicines and peptides studied for it are listed below.

Prescription medicines and peptides studied, for context

These are not supplements. Most need a prescription, and some are research compounds with no approved use.

1 medicine or peptide

Enfuvirtide (Fuzeon)

Enfuvirtide (Fuzeon): outcomes studied for HIV Infection
GradeOutcomeEffectSizeStudiesPeopleStudies list
Viral Load Reduction

Phase III: Superior virological activity vs optimized background regimen alone at 24 weeks in treatment-experienced patients.

Improves (the measure goes down)Large effect14 studies

Studies that measured viral load reduction

and 11 more on the Enfuvirtide (Fuzeon) page

CD4 Count Improvement

Significant immunological improvement demonstrated in pivotal Phase III trials (TORO-1 and TORO-2).

Improves (the measure goes up)Moderate effect14 studies

Studies that measured cd4 count improvement

and 11 more on the Enfuvirtide (Fuzeon) page

Treatment-Experienced Efficacy

Effective in patients with documented resistance to NRTIs, NNRTIs, and PIs. Valuable rescue therapy option.

Improves (the measure goes up)Large effect14 studies

Studies that measured treatment-experienced efficacy

and 11 more on the Enfuvirtide (Fuzeon) page

Viral Suppression Rate

Higher proportion achieving viral suppression when added to optimized background therapy in clinical trials.

Improves (the measure goes up)Moderate effect14 studies

Studies that measured viral suppression rate

and 11 more on the Enfuvirtide (Fuzeon) page

Time to Treatment Failure

Prolonged time to virologic failure compared to control arm in Phase III studies.

Improves (the measure goes up)Moderate effect14 studies

Studies that measured time to treatment failure

and 11 more on the Enfuvirtide (Fuzeon) page

Key findings

  • Viral Load ReductionEnfuvirtide (Fuzeon)Improves (the measure goes down)
  • CD4 Count ImprovementEnfuvirtide (Fuzeon)Improves (the measure goes up)
  • Treatment-Experienced EfficacyEnfuvirtide (Fuzeon)Improves (the measure goes up)

Studies cited

14 studies from PubMed

  1. Fuzeon-induced collagenophagic granuloma: a peculiar granulomatous injection site reaction to Fuzeon--a case report and review of literature.International journal of surgical pathology, 2010 · PMID 19223380
  2. Enfuvirtide: a review of its use in the management of HIV infection.Drugs, 2005 · PMID 15907147
  3. Enfuvirtide, the first fusion inhibitor to treat HIV infectionAIDS Rev, 2005 · PMID 16302461
  4. Resistance to enfuvirtide, the first HIV fusion inhibitorJ Antimicrob Chemother, 2004 · PMID 15231762
  5. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infectionAntimicrob Agents Chemother, 2004 · PMID 14998221
  6. Clinical trials for enfuvirtide (Fuzeon, T-20).AIDS (London, England), 2003 · PMID 15065580
  7. Fuzeon data review.GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 2003 · PMID 12728857
  8. Enfuvirtide: the first HIV fusion inhibitorExpert Opin Pharmacother, 2003 · PMID 15794736
  9. Enfuvirtide: first fusion inhibitor for treatment of HIV infectionAm J Health Syst Pharm, 2003 · PMID 15259753
  10. Enfuvirtide: a fusion inhibitor for the treatment of HIV infectionDrugs Today (Barc), 2003 · PMID 15110129
  11. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and developmentAntiviral Res, 2003 · PMID 15219553
  12. Effects of vitamin C supplementation on gout risk: results from the physicians' health study II trialAm J Clin Nutr · PMID 35575611
  13. Lack of effect of tart cherry concentrate dose on serum urate in people with goutRheumatology · PMID 31891407
  14. Effect of omega-three supplementation on serum urate and gout flares in people with gout; a pilot randomized trial.BMC Rheumatol · PMID 35672866